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Abstract The Duffy blood group antigen is an essential
receptor for Plasmodium vivax entry into erythrocytes in a
process mediated by the parasite ligand, the Duffy binding
protein (DBP). Recently, individuals living in a malaria endemic
region of Papua New Guinea were identified as heterozygous for
a new allele conferring Duffy negativity, which results in 50%
less Duffy antigen on their erythrocytes. We demonstrate that
DBP adherence to erythrocytes is significantly reduced for
erythrocytes from heterozygous individuals who carry one Duffy
antigen negativity allele. These data provide evidence that
emergence of this new allelic form of Duffy negativity is
correlated with resistance against vivax malaria. ß 2001 Fed-
eration of European Biochemical Societies. Published by Elsev-
ier Science B.V. All rights reserved.
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1. Introduction
Malaria is a virulent disease caused by the Plasmodium
parasite, e⁄ciently propagating itself in the blood of its verte-
brate host. Innate resistance to malaria infections in humans
is conferred by various blood group polymorphisms. A well-
documented association between a benign human genetic trait
and reduced malaria prevalence involves the Du¡y blood
group antigen and Plasmodium vivax [1,2]. Since individuals
who are Du¡y-negative are refractory to invasion by P. vivax
merozoites, it has been presumed that Du¡y negativity in
humans arose because this imparted a natural resistance to
vivax malaria. Field observations from West Africa and
Ethiopia have indeed established a strong correlation between
absence or low endemicity of vivax malaria and the high
prevalence of the Du¡y negativity allele [3,4]. In vitro eryth-
rocyte invasion assays showed that Du¡y-negative but not
Du¡y-positive human erythrocytes were resistant to invasion
by P. knowlesi, a simian malaria parasite related to P. vivax
[5]. In addition, experimental infections of human volunteers
with P. vivax showed that Du¡y-negative individuals were
resistant to blood-stage infection [6]. These experiments dem-
onstrated that P. vivax requires the Du¡y blood group anti-
gen for merozoite invasion. In P. vivax, the merozoite ligand
that interacts with the Du¡y blood group antigen was identi-
¢ed as the Du¡y binding protein (DBP) [7] and is encoded by
a single-copy gene [8]. Experimental analysis of the DBP
showed that a cysteine-rich extracellular domain of this pro-
tein (so-called region II [9]) was the parasite ligand domain
interacting with the Du¡y blood group antigen on the host
erythrocyte [10]. Additionally, there was a correlation between
the ability of the DBP to bind erythrocytes and their suscep-
tibility to invasion by P. knowlesi and P. vivax merozoites
[7,10].
The human Du¡y blood group antigen is a transmembrane
glycoprotein of 35^43 kDa [11]. The Du¡y protein has been
identi¢ed as a receptor for chemokines and therefore was re-
named the Du¡y antigen receptor for chemokines (DARC)
[12]. Analysis of the encoding gene [13] led to the discovery
that the di¡erence between FY*A and FY*B alleles (Fya and
Fyb antigens, respectively) is due to a single nucleotide poly-
morphism (G131A), changing a Gly to Asp at residue 44
(FY*A and FY*B, respectively) [14,15]. Furthermore, the Duf-
fy-negative phenotype observed in black African populations
is caused by a single nucleotide polymorphism in the GATA
box of the DARC promoter (T46C), disrupting a binding site
for an erythroid transcription factor that results in a silent
FY*B allele in erythroid cell lineage [16]. This Du¡y-negative
phenotype was originally described and only found associated
with the FY*B allele. The same transition (T46C) in the
GATA box was recently identi¢ed in a population from Pap-
ua New Guinea linked to the FY*A allele, and this FY*Anull
mutation appears to have a more recent origin than that of
FY*Bnull [17]. All 23 individuals found with this new allele
were heterozygous (FY*A/FY*Anull). Flow cytometric analysis
revealed that these individuals expressed half the amount of
Du¡y antigen on their erythrocytes indicating a gene dosage
e¡ect. A de¢nitive conclusion could not be made on whether
these heterozygous individuals were less susceptible to infec-
tion with P. vivax.
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An in vitro binding assay has proved successful in studying
the interactions between the Du¡y antigen present on the
erythrocyte surface and its parasite ligand [10,18]. In this as-
say, the P. vivax DBP ligand domain expressed on the surface
of COS cells mediates cytoadherence to Du¡y-positive eryth-
rocytes. Using this assay, we found a signi¢cant reduction of
binding of heterozygous Du¡y-negative vs. homozygous Duf-
fy-positive erythrocytes.
2. Materials and methods
2.1. Blood samples
Blood samples were collected in Papua New Guinea into sodium
EDTA and shipped on wet ice to Cleveland. An aliquot of each
sample was then shipped overnight on wet ice to Notre Dame and
used in the binding assays approximately 2 weeks after collection.
Additional samples were collected at the American Red Cross Blood
Service as tube segments from blood collection bags, using citrate
phosphate dextrose as an anticoagulant. These samples were stored
under optimal conditions and used within 5 days of collection. All
blood samples were collected after obtaining informed consent follow-
ing protocols approved by the institutional review boards of Case
Western Reserve University and University Hospitals of Cleveland,
the American Red Cross of Cleveland and the University of Notre
Dame.
2.2. Du¡y antigen characterization
Surface expression of the Du¡y antigen was quantitated on a subset
of the blood samples by £ow cytometry using a Fy6 monoclonal anti-
body as reported previously. Expression levels were consistent with
those reported previously for the homozygous and heterozygous geno-
types [17].
2.3. Binding constructs
2.3.1. pRE4-DBPII . The pRE4 construct containing P. vivax dbp
region II was described earlier [10]. The vector contains the open
reading frame (ORF) of the herpes simplex virus glycoprotein D1
(HSVgD1), a type I integral membrane protein and expression is
driven by the Rous sarcoma virus long terminal repeat. The HSVgD1
ORF contains unique ApaI and PvuII restriction sites where PvDBPII
was cloned as a HSVgD1 chimera.
2.3.2. pEGFP-DBPII . A second HSVgD1/DBPII plasmid ex-
pressed this chimeric protein as a recombinant fusion at the N-termi-
nus of green £uorescent protein (GFP) as described previously [18].
2.3.3. pRE4-EBA-175. The pRE4 construct, encoding the region
II ligand domain of the P. falciparum EBA-175 as a HSVgD1 chimera
[19], was used as a control for binding speci¢city (Fig. 2A,B). All
recombinant plasmids were puri¢ed using an endotoxin-free plasmid
puri¢cation kit (Qiagen).
2.4. Fluorescence microscopy
Surface expression of COS-7 cells transfected with pRE4-DBPII was
detected by using monoclonal antibodies 1D3 and DL6 against
HSVgD1 epitopes remaining in the expression construct [20]. COS-7
cells transfected with pEGFP-DBPII were observed with an epi£uo-
rescence Nikon microscope (Fig. 1B).
2.5. Transfection of COS-7 cells and binding assays
COS-7 cells were transferred into 6-well culture plates and then
transfected with plasmid DNA (1 Wg per well) using Lipofectamine
(Gibco BRL) in Dulbecco’s modi¢ed Eagle’s medium (DMEM) (Sig-
ma). At 24 h after transfection, medium was replaced by DMEM with
10% fetal bovine serum and cells were incubated for a further 24 h.
After this treatment the transfected cells were incubated for 2 h at
room temperature with human erythrocytes of di¡erent Du¡y pheno-
types (1% ¢nal suspension, previously washed in DMEM without
serum). Cells were washed three times with phosphate-bu¡ered saline
to remove non-adherent erythrocytes. In 30 ¢elds of 200U magni¢-
cation, rosettes of adherent erythrocytes were scored as positive when
erythrocytes bound to more than 50% of the cell surface.
2.6. Statistical analysis
Statistical analyses were performed using StatView, version 4.51
(Abacus Concepts, Inc., Berkeley, CA, USA).
3. Results
P. vivax DBP region II (PvDBPII) mediates adhesion to
human erythrocytes that have DARC on their surface. Eryth-
rocyte adhesion by region II of the P. falciparum EBA-175
(PfEBAII) depends on a sialic acid-dependent receptor on gly-
cophorin A [19]. Erythrocyte cytoadherence activity of both
parasite ligand domains can be assayed when expressed on the
surface of COS-7 cells as chimeric molecules with the
HSVgD1. Human erythrocytes representing di¡erent Du¡y
blood group alleles were overlaid on the transfected COS-7
cells and cytoadherence activity was compared (Fig. 1A). The
PvDBPII expressed on the surface of COS-7 cells did not bind
homozygous Du¡y-negative erythrocytes (Fig. 2B). A signi¢-
cant decline in binding activity was observed with the hetero-
zygous Du¡y-positive/negative genotypes, both FY*A/
FY*Anull and FY*B/FY*Bnull, when compared to the homozy-
Fig. 1. Erythrocyte binding to P. vivax DBPII expressed on COS-7
cells as an N-terminal GFP fusion protein. A: Rosette of human er-
ythrocytes adherent to only the COS-7 cell expressing DBPII.
B: Cell-associated £uorescence due to the expression of the GFP
part of the fusion protein con¢rmed erythrocyte cytoadherence was
associated with DBPII expression.
Fig. 2. Binding to P. vivax DBP and P. falciparum EBA175 ligand
domains expressed on the surface of COS-7 cells (pRE4 plasmid) by
human erythrocytes with di¡erent Du¡y antigen genotypes. Percent-
age binding was expressed relative to the erythrocyte genotype
showing the highest number of rosettes for each binding construct.
A: Erythrocytes from Papua New Guinea. B: Erythrocytes from
North Americans. A/A: FY*A/FY*A ; A/3 : FY*A/FY*Anull ; B/B:
FY*B/FY*B ; B/3 : FY*B/FY*Bnull ; 3/3 : FY*Bnull/FY*Bnull.
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gous Du¡y-positive erythrocytes (FY*A/FY*A) and (FY*B/
FY*B) (Fig. 2A,B). In contrast, erythrocyte cytoadherence
to PfEBAII was not a¡ected by any Du¡y phenotype,
(FY*A/FY*Anull), (FY*B/FY*Bnull), (FY*A/FY*A), (FY*B/
FY*B), and FY*Bnull/FY*Bnull (Fig. 2A,B and data not
shown).
A more sensitive assay was then used to con¢rm the sig-
ni¢cant di¡erence of DBP erythrocyte cytoadherence for Duf-
fy-positive homozygotes (FY*B or FY*A) versus heterozygous
(FY*A or FY*B and FY*Anull or FY*Bnull) donor erythro-
cytes. The PvDBPII expressed as a recombinant fusion protein
to the N-terminus of the GFP allowed better assessment of
DBP cytoadherence activity [18]. Erythrocytes originating
from North American volunteers and processed under opti-
mal conditions were used in the cytoadherence assay as an
added assurance of accurately measuring di¡erences in DBP
cytoadherence properties for the di¡erent Du¡y phenotypes
irrespective of their FY*A or FY*B alleles. In these assays,
cytoadherence between the DBP ligand domain and erythro-
cytes from Du¡y promoter heterozygous donors was signi¢-
cantly reduced (Fig. 3). As expected, erythrocytes from the
homozygous Du¡y-negative individuals did not bind DBP
(Fig. 3).
4. Discussion
Malaria is an important selective force for human genetic
adaptations due to the sustained, lethal impact that it has had
on human populations around the world. Homozygosity for
the Du¡y-negative blood group antigen confers complete re-
sistance to vivax malaria. Nevertheless, it is unclear whether
selective pressure of vivax malaria alone was the main cause
for the emergence and ¢xation of the FY*Bnull/FY*Bnull gen-
otype in much of West Africa where vivax malaria is absent.
Indeed there is little doubt that malaria caused by P. vivax is
not as directly lethal as P. falciparum, but a fulminant P.
vivax infection still causes serious morbidity especially in those
living at the minimum subsistence level. The emergence of an
independent Du¡y-negative blood group allele in a region of
Papua New Guinea highly endemic for vivax malaria lends
credence to the theory that vivax malaria can act as a selective
agent [17].
Genetic epidemiological surveys conducted in Papua New
Guinea have so far only found individuals in whom the
FY*Anull allele has been heterozygous with FY*A. This new
FY*A/FY*Anull genotype conferred a 50% decrease for Du¡y
antigen expression on their erythrocytes when compared to
individuals who are homozygous Du¡y-positive. When pre-
vious studies compared erythrocytes with di¡erent Du¡y phe-
notypes from various hosts, a correlation was shown between
erythrocyte invasion of a particular type of erythrocyte and its
potential to bind the P. vivax DBP [7]. A similar phenomenon
was observed with the P. knowlesi DBP cytoadherence activity
and merozoite invasion e⁄ciency.
Previous studies have con¢rmed that heterozygous Du¡y-
negative individuals remain susceptible to infections by P.
vivax [21]. Using a DBP-speci¢c in vitro cytoadherence assay
we demonstrated that erythrocytes from FY*A/FY*Anull Pap-
ua New Guineans show a signi¢cant reduction in binding to
the DBP ligand when compared to erythrocytes from FY*A/
FY*A Papua New Guinea donors (Fig. 2A). The same was
observed when using erythrocytes from heterozygous
(FY*Bnull/FY*B, FY*Bnull/FY*A) North American donors
(Figs. 2B and 3). These results support the previous observa-
tion [17] of an association between the heterozygous FY*A/
FY*Anull genotype and a reduced prevalence of P. vivax in-
fection. The prevalence of infection in the small study popu-
lation was not statistically signi¢cant and probably will re-
quire a larger study population and inclusion of additional
clinical parameters.
It is too early to a⁄rm that the Du¡y-negative allele was
selected by the vivax malaria endemicity in the Papua New
Guinea study population. Nevertheless, our results suggest
that even at the heterozygous state the Du¡y-negative allele
can confer a quanti¢able resistance advantage against P. vi-
vax. Our previous study demonstrated that naturally acquired
and vaccine-elicited antibodies blocked erythrocyte cytoadher-
ence of the P. vivax DBP [18]. These data showed that a
naturally acquired immunological response against the P. vi-
vax DBP can e¡ectively block the vital receptor binding func-
tion of this merozoite protein. Unfortunately, such an e¡ec-
tive high titer anti-DBP inhibitory response was found to be
relatively rare (V10%) even among residents living in highly
endemic regions of Papua New Guinea. Instead, individuals
from this region were characterized by a poorly inhibitory,
low titer antibody response [22]. Overall, our studies suggest
that the heterozygous FY*A/FY*Anull genotype may enhance
e⁄cacy of a poorly inhibitory anti-DBP antibody response.
Potentially, FY*A/FY*Anull individuals are then better able to
control the P. vivax growth rate and su¡er less morbidity
from infection.
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